The Orphan Drug Market is expected to grow from USD 253.6 billion in 2025 to USD 398.6 billion in 2030, at a CAGR of 9.46%.
During the forecast period, prescription sales in the orphan drug sector are projected to grow at twice the rate of the overall prescription market. However, various government authorities encourage to development and market of orphan drugs. The cost incurred during the research and development of orphan drugs is higher when compared with non-orphan drugs. The orphan drug market is classified into various segments by disease types, indication, and geographical regions. In the orphan drugs disease type segment, oncologic diseases occupied a significant share of the market and the segment is predicted to maintain the attained growth trend during the forecast period. This is due to the growing prevalence of different forms of rare cancers, such as leukemia, myeloma, angiosarcoma, and others prevalent in the patient population.
By Disease Type
The global orphan drug market is segmented into various types of diseases orphan drug manufacturing companies target, namely oncologic diseases, metabolic diseases, hematologic and immunologic diseases, infectious diseases, neurologic diseases, and other RARE Diseases. The Oncologic segment of the orphan drug market was the most dominant sector due to a large number of rare cancer form cases found in patients. The oncology segment is expected to maintain the trend and will be the key segment during the period of the next five years.
By Product Type
The global orphan drug market is segmented into two segments on basis of the origin of their components, biological or non-biological. The global orphan drug market is offering products that are driven by biological or non-biological sources. Biological products are costlier as extraction and purification take large investments and also sometimes sources may be rare which adds to the cost.
The global orphan drug market is expanding globally to cure rare diseases and is thus expected to grow in all regions. North America is estimated to have a significant market share due to the high number of research and development going on in the region coupled with the high medical costs and skilled labor force available in the region.
The orphan drug market is competitive owing to the presence of well-diversified global players. Various pioneer companies in the orphan drug market are Bayer, Amryt Pharma Plc.[1], Bristol-Myers Squibb Company, Novartis AG, Celgene Corporation, F. Hoffmann-La Roche AG, and Pfizer Inc. among others.
| Report Metric | Details |
|---|---|
| Total Market Size in 2025 | USD 253.6 billion |
| Total Market Size in 2030 | USD 398.6 billion |
| Forecast Unit | Billion |
| Growth Rate | 9.46% |
| Study Period | 2020 to 2030 |
| Historical Data | 2020 to 2023 |
| Base Year | 2024 |
| Forecast Period | 2025 – 2030 |
| Segmentation | Disease Type, Product Type, Geography |
| Geographical Segmentation | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies |
|